Synthesis of trans-(3R,5S)-Atorvastatin Ca and Curative Effect on Hyperlipidemia Induced by a High-Fat Diet in Rats

cis-(3R,5R)-Atorvastatin Ca (1) used for hyperlipidemia have four stereomers. However, It is very difficult to prepare stereoselective stereomers. In this paper, the reduction of 3,5-diketo atorvastatin ester (3) was performed using $Me_4NHB(OAc)_3$ in acetic acid as a reductant and showed excellent stereoselectivity in the double reduction of 3,5-diketo atorvastatin ester (3). As a result, reduction of compound 3 by $Me_4NHB(OAc)_3$ was purely obtained with cis-(3R,5R)-atorvastatin ester (4) of 1.5% and trans-(3R,5S)-atorvastatin ester (5) of 98.5%. Also, cis-(3R,5R)-atorvastatin Ca (1) and trans-(3R,5S)-atorvastatin Ca (7) were used to determine efficacy in the treatment of liver damage and hyperlipidemia induced by a high-fat diet in rats and to study the performance of the January 2010 experient was conducted. As a result, total cholesterol (TC), high-density lipoprotein-cholesterol (HDL-c), low-density lipoprotein-cholesterol (LDL-c), and triglyceride (TG) levels of compound 1 and 7 groups were $93.0{\pm}0.5$, $43.5{\pm}0.8$, $40.4{\pm}1.4$, $45.6{\pm}0.9\;mg/d{\ell}$ and $110.0{\pm}0.7$, $33.3{\pm}0.6$, $65.8{\pm}1.9$, $54.8{\pm}1.2\;mg/d{\ell}$, respectively. Atherogenic index (AI) and cardiac risk factor (CRF) in compound 1 and 7 were $1.14{\pm}0.05$, $2.14{\pm}0.05$ and $2.31{\pm}0.06$, $3.31{\pm}0.06$, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were $51.9{\pm}4.6$, $16.0{\pm}2.1\;IU/{\ell}$ and $75.8{\pm}4.4$, $35.1{\pm}9.7\;IU/{\ell}$. Taken together, while compound 1 treat against high-fat diet-induced hyperlipidemia by attenuating hepatic lipid depots and reducing oxidative stress, compound 7 group had a low curative effect on hyperlipidemia induced by a high-fat diet in rats. These findings suggest that new method about synthesis of stereoselective stereomers and indicate that it may consider using in a clinical trial.

trans-(3R,5S)-Atorvastatin Ca의 합성 및 Rat에서 고지방식이로 유도된 고지혈증 치료효과

고지혈증 치료제인 cis-(3R,5R)-atorvastatin Ca (1)은 4개의 입체이성질체가 있으며, 각각의 이성질체들을 선택적으로 제조한다는 것은 매우 어려운 일이다. 본 연구에서는 입체이성질체 중의 하나인 trans-(3R,5S)-atorvastatin Ca (7)을 초산에서 3,5-diketo atorvastatin ester (3)를 $Me_4NHB(OAc)_3$을 사용하여 환원시켜 cis-(3R,5R) (4)과 trans-(3R,5S)-atorvastatin ester (5)를 각각 1.5%와 98.5%의 비율로 입체선택적으로 제조할 수 있었다. 또한, 고지혈증 치료제인 cis-(3R,5R)-atorvastatin Ca (1)과 그의 입체이성질체인 trans-(3R,5S)-atorvastatin Ca (7)을 쥐에서 고지방식이에 의해 유발된 고지혈증의 치료효과에 대하여 알아보았고, 이러한 연구의 수행을 위해 2010년 1월에 실험을 실시하였다. 그 결과, 화합물 1과 7의 total cholesterol (TC), high-density lipoprotein-cholesterol (HDL-c), low-density lipoprotein-cholesterol (LDL-c)과 triglyceride (TG)는 각각 $93.0{\pm}0.5$, $43.5{\pm}0.8$, $40.4{\pm}1.4$, $45.6{\pm}0.9\;mg/d{\ell}$와 $110.0{\pm}0.7$, $33.3{\pm}0.6$, $65.8{\pm}1.9$, $54.8{\pm}1.2\;mg/d{\ell}$를 atherogenic index (AI)와 cardiac risk factor (CRF)는 $1.14{\pm}0.05$ $2.14{\pm}0.05$와 $2.31{\pm}0.06$, $3.31{\pm}0.06$을 나타냈으며 aspartate aminotransferase (AST)와 alanine aminotransferase (ALT)는 $51.9{\pm}4.6$, $16.0{\pm}2.1\;IU/{\ell}$와 $75.8{\pm}4.4$, $35.1{\pm}9.7\;IU/{\ell}$로 두 화합물 모두 고지혈증에 대한 치료효과를 나타내었으나, 화합물 1이 우수한 치료효과가 있는 반면 화합물 7은 치료효과가 낮은 것을 확인하였다. 이러한 결과들로 입체선택적 이성질체의 합성에 대한 새로운 방법을 제시하고, 향후 시판되고 있는 의약품들의 입체이성질체에 대한 임상적 활용이 가능할 것으로 사료된다.